Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients
REctal Organ Preservation With a BOost Approach Using CBCT-based Online Adaptive radioTherapy
Claudia Schuurhuizen
25 participants
Jan 27, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this prospective study is to evaluate if a higher radiation dose to the tumor can increase the organ preservation rate in non-locally advanced rectal cancer.
Eligibility
Inclusion Criteria7
- Age ≥18 years
- Eastern cooperative oncology group (ECOG) performance status ≤2
- Histologically confirmed rectal adenocarcinoma
- Non-locally advanced rectal cancer, defined as (magnetic resonance imaging (MRI)-based) T1-3, N0/N1 (≤3 positive mesorectal lymph nodes), MX/M0
- Indication for curative treatment with organ preservation
- Discussed in the multidisciplinary tumor board (MTB)
- Written informed consent
Exclusion Criteria8
- Previous radiotherapy in the pelvic area
- Other malignancies, except for adequately treated basal cell carcinoma (BCC), at time of inclusion or within 3 years prior to inclusion
- Contra-indications for (chemo)radiotherapy or surgery
- Presence of lateral lymph nodes, cN2 status, extramural vascular invasion (EMVI) or mesorectal fascia involvement as seen on MRI
- Mucinous defined tumor on MRI
- Prior local excision of the primary tumor
- DPD (dihydropyrimidine dehydrogenase) deficiency
- Unable to understand the requirements of the study and to give written informed consent, as determined by the treating physician
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Addition of a simultaneous integrated boost (SIB) to the standard chemoradiotherapy (CRT) scheme of 2.0 Gy to the mesorectum. The radiotherapy scheme consists of 25 fractions, delivering 2.0 Gy per fraction to the mesorectum and 2.4 Gy per fraction to the tumor and positive mesorectal lymph nodes.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07616297